Provided herein, among other things, is an engineered non-plant cell that produces a tropane alkaloid product, a precursor of a tropane alkaloid product, or a derivative of a tropane alkaloid product. A method for producing a tropane alkaloid, a precursor of a tropane alkaloid product, or a derivative of a tropane alkaloid product that makes use of the cell is also described.

The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding a branched chain amino acid catabolism enzyme. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders involving the catabolism of branched chain amino acids using the pharmaceutical compositions disclosed herein.

Sunscreen compositions and sunscreen active ingredients are disclosed herein which comprise at least one ketone-containing UV filter and at least one primary or secondary amine wherein at least one ketone-containing UV filter and at least one primary or secondary amine react to form an imine analog of the ketone-containing UV filter wherein the imine analog has at least one property selected from the group consisting of a) is capable of extending UV protection into a visible region equal to or greater than 400 nm, b) is water resistant, and/or c) prevents or decreases skin penetration. This imine analog may be further modified to provide a substrate capable of reacting with transglutaminase or any variant thereof and/or a lysyl oxidase to bind the sunscreen composition or sunscreen active ingredient to a target of interest. Also disclosed are cosmetic or pharmaceutical preparations comprising any of the sunscreen compositions or sunscreen ingredients along with a cosmetically or pharmaceutically acceptable carrier.

A method of producing high-purity hydroxy-L-pipecolic acids that includes allowing an L-pipecolic acid hydroxylase, a microorganism or cell having the ability to produce the enzyme, a processed product of the microorganism or cell, and/or a culture liquid comprising the enzyme and obtained by culturing the microorganism or cell, to act on L-pipecolic acid as a substrate in the presence of 2-oxoglutaric acid and ferrous ion, wherein the L-pipecolic acid hydroxylase (1) acts on L-pipecolic acid in the presence of 2-oxoglutaric acid and ferrous ion to add a hydroxy group to the carbon atom at positions 3, 4, and/or 5 of L-pipecolic acid; and (2) has a catalytic efficiency (kcat/Km) with L-proline that is equal to or less than 7 times the catalytic efficiency (kcat/Km) with L-pipecolic acid.

The invention refers to a recombinant human diamine oxidase (DAO) with decreased glycosaminoglycan binding affinity, wherein said DAO comprises at least one amino acid modification in the glycosaminoglycan (GAG) binding domain. The present invention also refers to the use of the DAO in the treatment of a condition associated with excess histamine, specifically in the treatment of chronic allergic diseases, more specifically in the treatment of anaphylaxis, anaphylactic shock, chronic urticaria, acute urticaria, asthma, hay fever, allergic rhinitis, allergic conjunctivitis, histamine intoxication, headache, atopic dermatitis inflammatory diseases, mastocytosis, mast cell activation syndrome (MCAS), pre-eclampsia, hyperemesis gravidarum, pre-term labor, peptic ulcers, acid reflux, pruritus, and sepsis.

The invention provided methods and devices for performing sequential, regulated multiplex reactions in a single tube without the addition or removal of contents from the tube.

The present invention relates to microbial host cells that have been engineered for increased tolerance to temperature shifts, for increased performance at temperatures different from the microorganism's optimal temperature and/or for changing at least one of the microorganism's cardinal temperatures by replacing an endogenous NAD.sup.+ biosynthesis gene by a heterologous gene encoding a corresponding enzyme with another temperature profile and/or from a microorganism with a different optimum growth temperature. The invention further relates to processes wherein the engineered microbial host cells are used for producing a fermentation product, and to the use nucleotide sequences encoding NAD.sup.+ biosynthesis gene for changing at least one of a microorganism's cardinal temperatures and/or for improving a microorganism's tolerance to temperature shifts.

A method of bonding together surfaces of two or more elements. The method includes the steps of providing two or more elements, applying an adhesive to one or more of the surfaces to be bonded together before, during or after contacting the surfaces to be bonded together with each other, and curing the adhesive, wherein the adhesive comprises at least one hydrocolloid.

A method is provided for measuring glycated hemoglobin in a hemoglobin-containing sample which comprises reacting glycated hemoglobin in the hemoglobin-containing sample with an enzyme that catalyzes a reaction of oxidizing the glycated hemoglobin to generate hydrogen peroxide, in the presence of at least one anionic surfactant selected from the group consisting of N-acyl taurine in which a hydrogen atom of the amino group may be substituted with a substituent, alkyl sulfoacetic acid, polyoxyethylene alkyl ether acetic acid, N-acyl amino acid in which a hydrogen atom of the amino group may be substituted with a substituent, polyoxyethylene alkyl ether phosphoric acid, polyoxyethylene polycyclic phenyl ether phosphoric acid, alkyl phosphoric acid, and salts thereof, to generate hydrogen peroxide, and measuring the generated hydrogen peroxide.

The disclosure discloses preparation of an L-amino acid deaminase mutant and application thereof, belonging to the technical field of gene engineering. Through pmirLAAD protein modification, analysis of a flexible loop structure around a binding site of the pmirLAAD product, and design of the best mutant, the modification method of the disclosure overcomes the defect that the catalytic efficiency of the previous wild-type enzyme is reduced due to product inhibition, and is tested by experiments. Compared with the control, the catalytic efficiency (1.61 mM.sup.−1.Math.min.sup.−1) and the product inhibition constant (5.4 mM) of the finally obtained best mutant pmirLAAD.sup.M4 are respectively increased by 5.2 times and 5.7 times. The yield of α-ketoisovaleric acid can reach 96.5 g/L, and the transformation rate is greater than 97%. By adopting the method of the disclosure, the cost can be greatly reduced, and the industrialization process of production of α-ketoisovaleric acid by an enzymatic transformation method is accelerated.